Aditxt IncNASDAQ:ADTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3245
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.3210/ 20
- Ask / Lots0.3390/ 5
- Open / Previous Close--- / 0.3245
- Day Range---
- 52 Week Range
- Volume17,832
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADTX |
|---|---|---|
| 09:32 ET | 6820 | 0.332 |
| 09:35 ET | 10000 | 0.3388 |
| 09:39 ET | 500 | 0.335 |
| 09:42 ET | 180 | 0.3353 |
| 09:44 ET | 796 | 0.3315 |
| 09:46 ET | 12834 | 0.3349 |
| 09:48 ET | 3291 | 0.3325 |
| 09:50 ET | 1311 | 0.33 |
| 09:51 ET | 9548 | 0.3299 |
| 09:53 ET | 200 | 0.33 |
| 09:55 ET | 140 | 0.33 |
| 09:57 ET | 300 | 0.326201 |
| 10:00 ET | 800 | 0.33 |
| 10:02 ET | 1395 | 0.3249 |
| 10:04 ET | 66577 | 0.321 |
| 10:06 ET | 7058 | 0.3201 |
| 10:08 ET | 9525 | 0.3218 |
| 10:09 ET | 4350 | 0.32 |
| 10:11 ET | 9261 | 0.3212 |
| 10:13 ET | 11521 | 0.3249 |
| 10:15 ET | 1125 | 0.321728 |
| 10:18 ET | 440 | 0.3241 |
| 10:22 ET | 1000 | 0.3241 |
| 10:24 ET | 1000 | 0.32305 |
| 10:26 ET | 378 | 0.322 |
| 10:27 ET | 300 | 0.3221 |
| 10:31 ET | 700 | 0.3241 |
| 10:38 ET | 100 | 0.3241 |
| 10:40 ET | 11049 | 0.3221 |
| 10:44 ET | 2886 | 0.322 |
| 10:45 ET | 5129 | 0.32005 |
| 10:47 ET | 6779 | 0.32 |
| 10:49 ET | 1721 | 0.32 |
| 10:51 ET | 2300 | 0.32 |
| 10:54 ET | 14702 | 0.32 |
| 10:56 ET | 10100 | 0.3201 |
| 10:58 ET | 3580 | 0.32005 |
| 11:00 ET | 5145 | 0.3201 |
| 11:02 ET | 1576 | 0.32015 |
| 11:03 ET | 100 | 0.3202 |
| 11:05 ET | 20238 | 0.3202 |
| 11:09 ET | 1000 | 0.32015 |
| 11:12 ET | 1150 | 0.3201 |
| 11:14 ET | 5617 | 0.32 |
| 11:16 ET | 6943 | 0.318 |
| 11:18 ET | 7657 | 0.316391 |
| 11:20 ET | 4100 | 0.3202 |
| 11:23 ET | 200 | 0.32 |
| 11:25 ET | 430 | 0.317192 |
| 11:27 ET | 11468 | 0.32 |
| 11:30 ET | 400 | 0.32 |
| 11:32 ET | 1143 | 0.3165 |
| 11:34 ET | 7861 | 0.324 |
| 11:36 ET | 2287 | 0.319 |
| 11:38 ET | 308 | 0.32 |
| 11:45 ET | 5488 | 0.32 |
| 11:48 ET | 1100 | 0.32 |
| 11:54 ET | 200 | 0.3225 |
| 11:56 ET | 3920 | 0.324 |
| 11:57 ET | 11059 | 0.3186 |
| 12:08 ET | 15935 | 0.3201 |
| 12:12 ET | 225 | 0.3201 |
| 12:14 ET | 16400 | 0.3211 |
| 12:15 ET | 1100 | 0.3213 |
| 12:17 ET | 800 | 0.3213 |
| 12:19 ET | 6073 | 0.3214 |
| 12:21 ET | 100 | 0.3217 |
| 12:39 ET | 6032 | 0.322 |
| 12:42 ET | 300 | 0.3222 |
| 12:44 ET | 9000 | 0.3226 |
| 12:46 ET | 100 | 0.3286 |
| 12:48 ET | 15000 | 0.3286 |
| 12:50 ET | 40372 | 0.326833 |
| 12:51 ET | 507 | 0.33505 |
| 12:53 ET | 1000 | 0.33505 |
| 01:02 ET | 300 | 0.3347 |
| 01:09 ET | 900 | 0.331 |
| 01:11 ET | 190 | 0.3324 |
| 01:18 ET | 1180 | 0.33 |
| 01:24 ET | 2500 | 0.3284 |
| 01:26 ET | 600 | 0.3251 |
| 01:27 ET | 49671 | 0.3205 |
| 01:29 ET | 1400 | 0.3214 |
| 01:31 ET | 500 | 0.323799 |
| 01:36 ET | 125 | 0.3226 |
| 01:38 ET | 1000 | 0.324999 |
| 01:40 ET | 10484 | 0.3229 |
| 01:42 ET | 370 | 0.325 |
| 01:44 ET | 1200 | 0.32457 |
| 01:45 ET | 22581 | 0.3255 |
| 01:47 ET | 100 | 0.3283 |
| 01:58 ET | 100 | 0.3226 |
| 02:03 ET | 154 | 0.323 |
| 02:07 ET | 154 | 0.3246 |
| 02:09 ET | 1000 | 0.3227 |
| 02:12 ET | 135 | 0.3247 |
| 02:16 ET | 400 | 0.3226 |
| 02:18 ET | 400 | 0.321 |
| 02:21 ET | 600 | 0.3226 |
| 02:30 ET | 1000 | 0.3203 |
| 02:32 ET | 500 | 0.3203 |
| 02:34 ET | 500 | 0.3203 |
| 02:36 ET | 1000 | 0.3203 |
| 02:39 ET | 2999 | 0.3204 |
| 02:41 ET | 800 | 0.3246 |
| 02:45 ET | 250 | 0.322501 |
| 02:48 ET | 1000 | 0.3245 |
| 02:50 ET | 1500 | 0.3246 |
| 02:52 ET | 1558 | 0.3221 |
| 02:54 ET | 2147 | 0.322 |
| 02:59 ET | 4553 | 0.3245 |
| 03:06 ET | 1000 | 0.323726 |
| 03:12 ET | 3450 | 0.3205 |
| 03:24 ET | 900 | 0.3228 |
| 03:26 ET | 4376 | 0.3221 |
| 03:28 ET | 900 | 0.3216 |
| 03:30 ET | 2521 | 0.3221 |
| 03:32 ET | 5800 | 0.3236 |
| 03:35 ET | 868 | 0.3205 |
| 03:37 ET | 900 | 0.320372 |
| 03:39 ET | 1545 | 0.3204 |
| 03:44 ET | 100 | 0.32295 |
| 03:46 ET | 1000 | 0.3227 |
| 03:48 ET | 331 | 0.3214 |
| 03:50 ET | 278524 | 0.3204 |
| 03:51 ET | 23767 | 0.3212 |
| 03:53 ET | 1800 | 0.3244 |
| 03:55 ET | 200 | 0.3223 |
| 03:57 ET | 1883 | 0.3221 |
| 04:00 ET | 5797 | 0.3245 |
Nov 19, 2024
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc., from 7:17AM ET on Tuesday Nov 19, 2024 by Dow Jones
7:17AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 14, 2024
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024, from 4:36PM ET on Thursday Nov 14, 2024 by Dow Jones
4:36PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024, from 4:36PM ET on Thursday Nov 14, 2024 by Dow Jones
4:36PM ET on Thursday Nov 14, 2024 by Dow JonesAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025, from 7:15AM ET on Thursday Nov 14, 2024 by Dow Jones
7:15AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 8, 2024
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares, from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones
8:30AM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aditxt Inc | 2.8M | 0.0x | --- |
Biodexa Pharmaceuticals PLC | 2.6M | 0.0x | --- |
Azitra Inc | 3.6M | -0.1x | --- |
Lipella Pharmaceuticals Inc | 2.9M | -0.5x | --- |
Oncternal Therapeutics Inc | 3.4M | -0.1x | --- |
Cyclacel Pharmaceuticals Inc | 2.2M | 0.0x | --- |
Company Information
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Contact Information
- Headquarters
- 737 N. Fifth Street, Suite 200RICHMOND, VA, United States 23219
- Phone
- 909-488-0844
- Fax
- 302-697-4597
Executives
- Chairman of the Board, Chief Executive Officer
- Amro Albanna
- Chief Financial Officer
- Thomas Farley
- Chief Operating Officer
- Rowena Albanna
- Chief Innovation Officer, Director
- Shahrokh Shabahang
- Chief Mergers & Acquisitions Officer
- Corinne Pankovcin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8M |
|---|---|
Revenue (TTM) | $329.8K |
Shares Outstanding | 8.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.00 |
EPS | $-3,088.09 |
Book Value | $487.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 8.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -10,224.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
